Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine.

Abstract excerpt

Sickle cell disease and thalassemia have distinctly different mutations, but both share common complications from a chronic vasculopathy. In the past, fetal hemoglobin-modulating drugs have been the main focus of new therapy, but the increased understanding of the complex pathophysiology of these diseases has led to the development of novel agents targeting multiple pathways that cause vascular injury. This...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anemia, Sickle Cell
• Share to Antioxidants
• Share to Clinical Trials as Topic